Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 14/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CPT2 | P23786 | 3/20 | 0.39 |
| ▸ | CPT1A | P50416 | 3/20 | 0.39 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16645229 | 0.94 | NAMPT (0.67) | NAMPTMAPTCPT2CPT1AACVR1 | |
| SCHEMBL16634756 | 0.89 | NAMPT (0.67) | NAMPTMAPTCPT2CPT1AACVR1 | |
| SCHEMBL16634820 | 0.89 | NAMPT (0.70) | NAMPTMAPTCPT2CPT1AACVR1 | |
| SCHEMBL16634725 | 0.87 | NAMPT (0.63) | NAMPTMAPTCPT2CPT1AACVR1 | |
| SCHEMBL16634780 | 0.86 | NAMPT (0.67) | NAMPTMAPTCPT2CPT1AACVR1 | |
| SCHEMBL16645201 | 0.85 | NAMPT (0.68) | NAMPTMAPTACVR1 | |
| SCHEMBL16645204 | 0.82 | NAMPT (0.52) | NAMPTMAPTCPT2CPT1A | |
| SCHEMBL16634834 | 0.81 | NAMPT (0.75) | NAMPTMAPTCPT2CPT1AACVR1 | |
| SCHEMBL17969249 | 0.79 | NAMPT (0.52) | NAMPTMAPTCPT2CPT1A | |
| SCHEMBL16634908 | 0.77 | NAMPT (0.70) | NAMPTMAPTCPT2CPT1AACVR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160229835-A1 | NOVEL PYRIDYLOXYACETYL TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS NAMPT INHIBITORS | ELI LILLY AND COMPANY | 2016-08-11 | — | — | US | disclosed |
| US-20160229835-A1 | NOVEL PYRIDYLOXYACETYL TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS NAMPT INHIBITORS | ELI LILLY AND COMPANY | 2016-08-11 | — | — | US | disclosed |
| US-20160229835-A1 | NOVEL PYRIDYLOXYACETYL TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS NAMPT INHIBITORS | ELI LILLY AND COMPANY | 2016-08-11 | — | — | US | disclosed |
| WO-2015054060-A1 | NOVEL PYRIDYLOXYACETYL TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS NAMPT INHIBITORS | ELI LILLY AND COMPANY (US) | 2015-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160229835-A1 | NOVEL PYRIDYLOXYACETYL TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS NAMPT INHIBITORS | NAMPT, NAPRT, NNMT | NAMPT 1/4885MAPT 1037/4885CPT2 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.